First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study

AV Balar; D Castellano; PH O'Donnell; P Grivas; J Vuky; T Powles; ER Plimack; NM Hahn; Ronald de Wit; L Pang; MJ Savage; RF Perini; SM Keefe; D Bajorin; J Bellmunt

doi:10.1016/s1470-2045(17)30616

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study

AV Balar
, D Castellano
, PH O'Donnell
, P Grivas
, J Vuky
, T Powles
, ER Plimack
, NM Hahn
, Ronald de Wit
, L Pang
, MJ Savage
, RF Perini
, SM Keefe
, D Bajorin
, J Bellmunt

Medical Oncology

Research output: Contribution to journal › Article › Academic › peer-review

1152 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	1483-1492
Number of pages	10
Journal	Lancet Oncology
Volume	18
Issue number	11
DOIs	https://doi.org/10.1016/s1470-2045(17)30616
Publication status	Published - 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Research programs

EMC MM-03-86-08

Access to Document

10.1016/s1470-2045(17)30616

Cite this

Balar, AV., Castellano, D., O'Donnell, PH., Grivas, P., Vuky, J., Powles, T., Plimack, ER., Hahn, NM., de Wit, R., Pang, L., Savage, MJ., Perini, RF., Keefe, SM., Bajorin, D., & Bellmunt, J. (2017). First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncology, 18(11), 1483-1492. https://doi.org/10.1016/s1470-2045(17)30616

@article{7678c9bf375f4acfb4db1c72bc54e102,

title = "First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study",

author = "AV Balar and D Castellano and PH O'Donnell and P Grivas and J Vuky and T Powles and ER Plimack and NM Hahn and \{de Wit\}, Ronald and L Pang and MJ Savage and RF Perini and SM Keefe and D Bajorin and J Bellmunt",

year = "2017",

doi = "10.1016/s1470-2045(17)30616",

language = "Undefined/Unknown",

volume = "18",

pages = "1483--1492",

journal = "Lancet Oncology",

issn = "1470-2045",

publisher = "Elsevier Ltd.",

number = "11",

}

Balar, AV, Castellano, D, O'Donnell, PH, Grivas, P, Vuky, J, Powles, T, Plimack, ER, Hahn, NM, de Wit, R, Pang, L, Savage, MJ, Perini, RF, Keefe, SM, Bajorin, D & Bellmunt, J 2017, 'First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study', Lancet Oncology, vol. 18, no. 11, pp. 1483-1492. https://doi.org/10.1016/s1470-2045(17)30616

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. / Balar, AV; Castellano, D; O'Donnell, PH et al.
In: Lancet Oncology, Vol. 18, No. 11, 2017, p. 1483-1492.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study

AU - Balar, AV

AU - Castellano, D

AU - O'Donnell, PH

AU - Grivas, P

AU - Vuky, J

AU - Powles, T

AU - Plimack, ER

AU - Hahn, NM

AU - de Wit, Ronald

AU - Pang, L

AU - Savage, MJ

AU - Perini, RF

AU - Keefe, SM

AU - Bajorin, D

AU - Bellmunt, J

PY - 2017

Y1 - 2017

U2 - 10.1016/s1470-2045(17)30616

DO - 10.1016/s1470-2045(17)30616

M3 - Article

SN - 1470-2045

VL - 18

SP - 1483

EP - 1492

JO - Lancet Oncology

JF - Lancet Oncology

IS - 11

ER -